GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and ...
Harvard Medical School’s Emily S. Wan, MD, discusses mucus plugs in COPD, how to detect them, and what would make them a treatment target.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was ...
The University of Exeter’s David Halpin, MA, DPhil, discusses inhaler device selection, single vs multiple inhalers, and the pharmacist’s role in COPD.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients ...
Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening ...
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election require ...
Interleukin 33 (IL-33) biology differs from type 2 (T2) inflammation in ways that could allow biologic therapy to reach patients with chronic obstructive pulmonary disease (COPD) regardless of blood ...
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded ...
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap ...
Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.
No systemic scalp psoriasis therapy raised serious adverse event risk in a network meta-analysis; only apremilast increased discontinuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results